Atara Biotherapeutics, Inc.
NASDAQ:ATRABiotechnology
+$0.19 today
- Market cap
- $68.98M
- Beta
- 0.11
- P/E (TTM)
- -14.7
- EPS (TTM)
- -$0.67
Volume 0.02M
Average 1.40M
ATRA Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Atara Biotherapeutics, Inc.NASDAQ: ATRA
Operating Margin · Q1 FY2026 · quarter ended Mar 2026
Operating margin narrows to -652.9%
Operating margin was -652.9% in Q1 FY2026, down 692.4 pp from a year earlier. On a trailing-twelve-month basis it was -27.3%, down 20.6 pp year over year. Over 3 fiscal years it widened by 470.9 pp.
Context
- Operating margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether operating margin reaches the consensus estimate from 1 analysts of -226.4% for the fiscal year ending Dec 2026, down from 29.7% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -652.9%-492.2 pp QoQ
- Last fiscal yearDec 2025
- 29.7%+94.4 pp YoY
- LTMMar 2026
- -27.3%-20.6 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 29.7%
- Year-over-year change
- +94.4pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 29.7% | +94.4pp |
| FY2024 | 2024-12-31 | -64.7% | +3154.8pp |
| FY2023 | 2023-12-31 | -3219.5% | -2778.2pp |
| FY2022 | 2022-12-31 | -441.2% | +1232.6pp |
| FY2021 | 2021-12-31 | -1673.9% | — |
Operating Margin vs competitors
How ATRA compares with its peers on the latest reported figures
- ATRA's LTM Mar 2026 operating margin of -27.3% is the 2nd highest of the 10 companies compared; the peer median is -670.2%.
- Its year-over-year change of -20.6 pp is the 6th highest of 9, against a peer median of +5.1 pp.
- Over three fiscal years its change of +470.9 pp compares with a peer median of +87.9 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jan 2026 | -3.8% | -14.6 pp | +7.3 pp | |
| LTM Mar 2026 | -27.3% | -20.6 pp | +470.9 pp | |
| LTM Mar 2026 | -40.5% | +24.7 pp | +32.2 pp | |
| LTM Mar 2026 | -115.5% | +261.4 pp | +87.9 pp | |
| LTM Mar 2026 | -277.0% | +250.6 pp | — | |
| LTM Mar 2026 | -670.2% | +9733.9 pp | +3111.2 pp | |
| FY2025 | -754.4% | — | +747.6 pp | |
| LTM Mar 2026 | -5266.4% | -3640.0 pp | +10697.2 pp | |
| LTM Mar 2026 | -15535.1% | -7553.1 pp | -1307.0 pp | |
| LTM Mar 2026 | -144445.0% | -103193.3 pp | — | |
| FY2025 | — | — | — | |
| Peer median (excluding ATRA) | -670.2% | +5.1 pp | +87.9 pp | |
Competitors are the stored peer set for ATRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 20.34M | 63.57M | 8.57M | 128.94M | 120.77M |
| Cost of Revenue | 282M | 269.99M | 8.89M | 21.01M | 21.21M |
| Gross Profit | (261.66M) | (206.42M) | (313K) | 107.93M | 99.56M |
| Gross Margin | -1286.4% | -324.7% | -3.7% | 83.7% | 82.4% |
| Research & Development | 282M | 272.53M | 224.79M | 151.48M | 37.45M |
| Selling, General & Admin | 78.8M | 68.13M | 50.91M | 39.89M | 26.25M |
| Operating Expenses | 78.8M | 74.1M | 275.69M | 191.37M | 63.7M |
| Depreciation & Amortization | 9.35M | 5.65M | 4.83M | 5.05M | 2.12M |
| EBITDA | (330.75M) | (222.26M) | (266M) | (75.75M) | 38.63M |
| EBITDA Margin | -1626.1% | -349.6% | -3102.7% | -58.7% | 32.0% |
| Operating Income | (340.46M) | (280.51M) | (276.01M) | (83.44M) | 35.86M |
| Operating Margin | -1673.9% | -441.2% | -3219.5% | -64.7% | 29.7% |
| Interest Income | 367K | 3.06M | 5.43M | 2.11M | 683K |
| Interest Expense | 0 | 373K | 5.29M | 4.62M | 3.79M |
| Other Income / Expenses | 367K | 52.22M | (105K) | (1.98M) | (3.14M) |
| Income Before Tax | (340.1M) | (228.29M) | (276.11M) | (85.42M) | 32.72M |
| Pre-Tax Margin | -1672.1% | -359.1% | -3220.7% | -66.2% | 27.1% |
| Income Tax Expense | 46K | 12K | 15K | (12K) | 31K |
| Net Income | (340.14M) | (228.3M) | (276.13M) | (85.4M) | 32.69M |
| Net Margin | -1672.3% | -359.1% | -3220.9% | -66.2% | 27.1% |
| EPS (Basic) | (90.78) | (55.96) | (65.18) | (11.41) | 2.61 |
| EPS (Diluted) | (90.78) | (55.96) | (65.18) | (11.41) | 2.57 |
| Weighted Avg Shares | 3.75M | 4.08M | 4.24M | 7.49M | 12.54M |
| Weighted Avg Shares (Diluted) | 3.75M | 4.08M | 4.24M | 7.49M | 12.72M |
Atara Biotherapeutics, Inc.
NASDAQ:ATRA
Intrinsic Alpha fair value
Locked
Current Price
$6.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.